Article
Clinical Neurology
Sanjit Shah, Saima Manzoor, Yehudit Rothman, Matthew Hagen, Luke Pater, Karl Golnik, Abdelkader Mahammedi, Andrew L. L. Lin, Ruchi Bhabhra, Jonathan A. A. Forbes, Soma Sengupta
Summary: This is a case report highlighting the utility of immunotherapy in treating aggressive pituitary adenomas (APAs). The patient experienced complete resolution of recurrent APA and improved survival compared to the expected life expectancy. APAs are tumors with frequent recurrence and short median expected length of survival.
Review
Oncology
Barbara Seliger, Chiara Massa
Summary: The genetic adaptability and heterogeneity of malignant cells pose significant challenges to cancer treatment. While immune therapy shows promise in addressing these challenges, resistance to immunotherapies remains a common issue that needs to be overcome for successful treatment outcomes.
Article
Chemistry, Multidisciplinary
Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min
Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.
Review
Chemistry, Multidisciplinary
Elham Masoumi, Sahar Tahaghoghi-Hajghorbani, Leila Jafarzadeh, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Davood Bashash
Summary: This review provides an overview of the current research status of immune checkpoint blockades in breast cancer and discusses the efficacy and limitations of ICB therapy in breast cancer treatment.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Immunology
Mohammad Hossein Kazemi, Alireza Najafi, Jafar Karami, Foad Ghazizadeh, Hassan Yousefi, Reza Falak, Elahe Safari
Summary: Recent advancements in cancer immunotherapy, particularly immune checkpoint (IC) blockers, have shown promising results in clinical settings. Immunometabolism plays a crucial role in regulating immune responses, and dual targeting of ICs and metabolic pathways may help restore immune cells' antitumor activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Qi-jie Zhang, Jiao-chen Luan, Le-bin Song, Rong Cong, Cheng-jian Ji, Xiang Zhou, Jia-dong Xia, Ning-hong Song
Summary: The study found no difference in efficacy between elderly and young patients in most cancer types, except for melanoma patients receiving anti-PD-1 therapy. Elderly patients showed higher treatment response rate and more favorable prognosis in certain cancer types, potentially attributed to their high mutational properties. This suggests that modulating immune function could be beneficial to immunotherapy in elderly patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou
Summary: A nanocarrier that achieves self-blockade of PD-L1 in tumor cells and a detection kit to quantitatively measure the binding rate of PD-1/PD-L1 have been developed, improving the efficacy of PD-1/PD-L1 self-blocking therapy.
ADVANCED MATERIALS
(2022)
Article
Medicine, General & Internal
Sergio Di Molfetta, Tiziana Feola, Giuseppe Fanciulli, Tullio Florio, Annamaria Colao, Antongiulio Faggiano
Summary: Lung carcinoids are rare neuroendocrine neoplasms of the lung, and there is currently no global consensus on their systemic treatment. In recent years, immune checkpoint inhibitors have gained attention in the treatment of neuroendocrine neoplasms, and preliminary evidence shows the potential efficacy of combined nivolumab plus ipilimumab and durvalumab plus tremelimumab regimens in advanced and/or metastatic lung carcinoids.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Jing Yang, Shilin Zhao, Jing Wang, Quanhu Sheng, Qi Liu, Yu Shyr
Summary: Cancer-Immu is a comprehensive platform that integrates various omics data and clinical phenotypes to explore immunogenomic connections. It provides easy access to data and helps researchers translate omics datasets into biological insights and clinical applications.
Article
Immunology
Yaping Chen, Hao Huang, Yuan Li, Wenlu Xiao, Yingting Liu, Rongzhang Chen, Yulan Zhu, Xiao Zheng, Changping Wu, Lujun Chen
Summary: Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in cancer treatment, and the combination of ablation and immunotherapy has potential for the treatment of liver metastasis of colorectal cancer (CRC). The expression of TIGIT was up-regulated after microwave ablation (MWA), and the combination of MWA and TIGIT blockade significantly promoted the expansion and functions of CD8(+) tumor-infiltrating lymphocytes (TILs) and reshaped myeloid cells in the tumor microenvironment (TME).
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Neurosciences
Zuocheng Yang, Xuemei Tian, Kun Yao, Yakun Yang, Linpeng Zhang, Ning Liu, Changxiang Yan, Xueling Qi, Song Han
Summary: This study aimed to explore the relationship between aggressiveness and immune cell infiltration in pituitary adenoma (PA) and provide a basis for immuno-targeting therapies. The infiltration of macrophages and T-lymphocytes was quantitatively assessed in 103 PA patients. The results showed positive correlations between the number of CD68+ macrophages and Knosp grades, MMP-9 expression grades, as well as positive associations between CD8+ tumor-infiltrating lymphocytes (TILs) and Knosp grades, MMP-9 grades. Targeted therapy for macrophages and CD8+ TILs could be a helpful treatment for aggressive PA.
Review
Endocrinology & Metabolism
Antonio Bianchi, Sabrina Chiloiro, Antonella Giampietro, Simona Gaudino, Rosalinda Calandrelli, Ciro Mazzarella, Carmelo Caldarella, Mario Rigante, Marco Gessi, Liverana Lauretti, Laura De Marinis, Alessandro Olivi, Alfredo Pontecorvi, Francesco Doglietto
Summary: Growth hormone-secreting adenomas exhibit a wide range of behaviors and outcomes, from mild disease to aggressive neoplasms. Treatment for patients who do not respond to surgery or first-generation somatostatin receptor ligands may involve multiple surgical, medical, and radiation treatments. Currently, there are no markers that can predict the prognosis or aggressiveness of acromegaly. A multidisciplinary approach is necessary to tailor treatment for difficult/aggressive cases, including radiation therapy, chemotherapy, and emerging treatments.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Ming Zheng
Summary: This study demonstrates that the neutrophil-to-lymphocyte ratio (NLR) is a valuable indicator for predicting the outcomes of immune checkpoint blockade (ICB) treatment. An NLR range of 2.0 to 3.0 is associated with optimal treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Nanoscience & Nanotechnology
Qingzhi Wu, Moyuan Qu, Han-Jun Kim, Xingwu Zhou, Xing Jiang, Yi Chen, Jixiang Zhu, Li Ren, Tyler Wolter, Heemin Kang, Chun Xu, Zhen Gu, Wujin Sun, Ali Khademhosseini
Summary: The study demonstrates a minimally invasive strategy of locally delivering anti-PD 1 using shear-thinning biomaterials, offering a simple and efficient approach to deliver immune checkpoint inhibitors.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Review
Endocrinology & Metabolism
Jordan J. Wright, Douglas B. Johnson
Summary: Immune checkpoint inhibitors (ICI) are approved for use in various cancers and can stimulate immune cell responses against cancer. However, they can also cause toxicities in any organ system, with endocrine toxicities being common. These toxicities can range from mild cases of subclinical hypothyroidism to severe cases of adrenal crisis, thyroid dysfunction, or diabetic ketoacidosis. Timely recognition and treatment are crucial for managing ICI-associated endocrine dysfunction.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)